Expression of P2X7, P2X4, CD39 and CD73 in non-small cell lung cancer

Recruiting

• Conditions: C34; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00021114
• Lead Sponsor: niversitätsklinikum Freiburg Klinik für Thoraxchirurgie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. histologically proven NSCLC
2. Treatment of NSCLC at the Medical Center of University Freiburg between January 2003 and December 2019
3. signed Informed consent form of the Biobank of the Comprehensive Cancer Center Freiburg (CCCF)
4. sufficient tissue availability at the Biobank to perform all planned tests

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the expression of P2X7, P2X4, CD39 and CD73 in NSCLC-tissue

Secondary Outcome Measures

Name	Time	Method
to correlate the expression of P2X7, P2X4, CD39 and CD73 with the TNM-stadium, the overall survival and the relapse-free survival / interval.